COEPW Stock Price, Chart, Stats & News
Coeptis Therapeutics Holdings, Inc. (COEPW) does not currently pay a dividend.
COEPW chart
Fundamentals
Gross margin | -207.81% |
Operating margin | -956.94% |
Pretax margin | -900.72% |
Net margin | -874.29% |
Effective tax rate | 22.31% |
ROA | -60.06% |
ROE | -112.72% |
D/E | 0.02x |
Interest coverage ratio | -20.30x |
COEPW valuation
P/E | – |
P/S | 27.53x |
P/B | 2.62x |
P/CF | -5.26x |
P/FCF | -4.36x |
P/OCF | -5.26x |
PEG | 0.01x |
EV multiple | -3.63x |
About
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company dedicated to advancing both innovative cell therapy platforms and a pipeline of generic and branded pharmaceutical products, primarily targeting cancer patients. Its leading oncology assets include CD38-GEAR-NK, a Vy-Gen drug candidate engineered to combat CD38-positive cancers such as multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). Alongside this, the company offers CD38-Diagnostic, an in vitro screening tool designed to identify cancer patients who are most likely to respond favorably to targeted anti-CD38 monoclonal antibody treatments.
Similar securities
Based on sector and market capitalization
